scholarly journals Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations

2009 ◽  
Vol 63 (5) ◽  
pp. 1050-1057 ◽  
Author(s):  
A. H. Thomson ◽  
C. E. Staatz ◽  
C. M. Tobin ◽  
M. Gall ◽  
A. M. Lovering
Keyword(s):  
Dosage Guidelines ◽  
Vancomycin Dosage

Vitamin D overdose: Poor dosage guidelines for babies?

2015 ◽  
Author(s):  
Daniela Peeva ◽  
Benjamin Jacobs
Keyword(s):  
Vitamin D ◽  
Dosage Guidelines

Vancomycin dosage in overweight and obese children

2011 ◽  
Vol 68 (21) ◽  
pp. 2062-2068 ◽  
Author(s):  
Misty Miller ◽  
Jamie L. Miller ◽  
Tracy M. Hagemann ◽  
Donald Harrison ◽  
Susana Chavez-Bueno ◽  
...  
Keyword(s):  
Obese Children ◽  
Vancomycin Dosage

Increased Vancomycin Dosage Requirements in Young Burn Patients

1984 ◽  
Vol 5 (5) ◽  
pp. 376-378 ◽  
Author(s):  
George R. Bailie ◽  
Bruce H. Ackerman ◽  
James Fischer ◽  
Lynn D. Solem ◽  
John C. Rotschafer
Keyword(s):  
Burn Patients ◽  
Vancomycin Dosage

INDIVIDUALIZED PHARMACOKINETIC PROFILES TO COMPUTE VANCOMYCIN DOSAGE AND DOSING INTERVAL IN PRETERM INFANTS

1993 ◽  
Vol 12 (2) ◽  
pp. 156 ◽  
Author(s):  
Robert V. Jarrett ◽  
G. Andre Marinkovich ◽  
Everett L. Gayle ◽  
James W. Bass
Keyword(s):  
Preterm Infants ◽  
Dosing Interval ◽  
Pharmacokinetic Profiles ◽  
Vancomycin Dosage

scholarly journals Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections

2020 ◽  
Vol Volume 13 ◽  
pp. 685-695
Author(s):  
Sooyoung Shin ◽  
Hyun Joo Jung ◽  
Sang-Min Jeon ◽  
Young-Joon Park ◽  
Jung-Woo Chae ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Bacterial Infections ◽  
Pediatric Patients ◽  
Gram Positive ◽  
Vancomycin Dosage

scholarly journals Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

1990 ◽  
Vol 34 (6) ◽  
pp. 1165-1171 ◽  
Author(s):  
A K Hurst ◽  
M A Yoshinaga ◽  
G H Mitani ◽  
K A Foo ◽  
R W Jelliffe ◽  
...  
Keyword(s):  
Bayesian Method ◽  
Dosage Regimens ◽  
Vancomycin Dosage

A population model of epirubicin pharmacokinetics and application to dosage guidelines

2003 ◽  
Vol 52 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Lorraine D. Ralph ◽  
Alison H. Thomson ◽  
Nicola A. Dobbs ◽  
Chris Twelves
Keyword(s):  
Population Model ◽  
Dosage Guidelines

scholarly journals Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections

2020 ◽  
Vol 75 (10) ◽  
pp. 2933-2940
Author(s):  
Hinke Siebinga ◽  
Fiona Robb ◽  
Alison H Thomson
Keyword(s):  
Dose Adjustment ◽  
Population Pharmacokinetic ◽  
Limited Information ◽  
Once Daily ◽  
Mycobacterial Infections ◽  
Dosing Interval ◽  
Dosage Regimens ◽  
Population Pk ◽  
Post Infusion ◽  
Dosage Guidelines

Abstract Background There is limited information on amikacin pharmacokinetics (PK) and dose requirements in patients with mycobacterial infections. Objectives To conduct a population PK analysis of amikacin data from patients with mycobacterial infections and compare predicted concentrations from standard and modified dosage guidelines with recommended target ranges. Methods A population PK model was developed using NONMEM. Cmax, Cmin, concentration 1 h post-infusion (C1h) and AUC0–24 using 15 mg/kg daily (once daily), the WHO table, 25 mg/kg three times weekly (TTW) and modified guidelines were compared using Monte Carlo simulations of 1000 patients. Results Data were available from 124 patients (684 concentrations) aged 16–92 years. CL was 4.64 L/h per 100 mL/min CLCR; V was 0.344 L/kg. With once-daily regimens, Cmax was 35–45 mg/L in 30%–35% of patients and 35–50 mg/L in 46%–48%; C1h was 25–40 mg/L in 53%–59%. The WHO table produced high Cmax values in patients <60 kg and low in patients >75 kg. With TTW dosing, around 30% of Cmax values were 65–80 mg/L, 40% were 60–80 mg/L, and 48% of C1h were 45–65 mg/L. Increasing the dosage interval for patients with CLCR <50 mL/min reduced Cmin values >2 mg/L from 34% to 25% for once-daily dosing and from 18% to 13% for TTW. In patients whose Cmin was <2 mg/L, 82% of AUC0–24 values were 100–300 mg.h/L. Conclusions Standard amikacin dosing guidelines achieve low percentages of target concentrations for mycobacterial infections. Extending the dosing interval in renal impairment and widening target ranges would reduce the need for dose adjustment.

Sign in / Sign up

Export Citation Format

Share Document